ANGIOTENSIN CONVERTING ENZYMES (ACE) INHIBITORS MARKET ANALYSIS

Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Drugs (Benazepril, Perindopril, Trandfolapril, Captopril, Enalapril, Lisinopril, and Others (Ramipril, etc.), ), By Indication (Hypertension, Coronary Artery Disease, Heart Failure, Chronic Kidney Disease, Scleroderma, and Others (Migraine, etc.)), By Route of Administration (Oral and Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Recent Developments

On September 5, 2023, Pharmascience Canada, a Quebec-based pharmaceutical company, launched pms-PERINDOPRIL-INDAPAMIDE (perindopril erbumine or indapamide), a generic drug for adults for the initial treatment of mild to moderate essential hypertension (high blood pressure).
In July 2022, Solco Healthcare, a fully owned subsidiary of Prinston Pharmaceutical, Inc., a generic pharmaceutical company that develops, manufactures and markets generic pharmaceuticals products and Zhejiang Huahai Pharmaceutical, a multinational enterprise, committed to providing high-quality medical and health products announced that Enalapril Maleate tablets, 2.5mg, 5mg, 10mg, and 20mg, have received U.S. Food and Drug Administration (FDA) which are AB-rated equivalent to Vasotec by Bausch Health.
In February 2022, Camber Pharmaceuticals, a pharmaceutical company, announced the launch of Enalapril Maleate Oral Solution, a generic version of Epaned indicated for the treatment of hypertension, to lower blood pressure in adults and children older than one month.
On February 16, 2021, Zent2U, the B2B business of Zentiva Group, a.s., a biopharmaceutical company, announced the successful completion of the development on ACE inhibitor Perindopril Arginine.

Acquisition, Agreement, Collaboration and partnerships

In January 2020, AstraZeneca, one of the global biopharmaceutical companies, announced that it had signed an agreement with Atnahs Pharma (Atnahs), a specialty pharmaceutical business that acquires, markets, and develops mature branded medicines to sell the global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril), and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination).